Literature DB >> 11096584

Nonobstructing Crohn's Disease.

.   

Abstract

Although our existing medical management improves the quality of life of the majority of patients with Crohn's disease (CD), a substantial proportion of individuals still experience unpleasant symptoms from either the disease or therapy. Many patients ultimately require surgery. In the near future it is highly likely that new drugs will be available that are able to favorably modify the natural history of the disease.

Entities:  

Year:  1999        PMID: 11096584     DOI: 10.1007/s11938-999-0041-2

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN: 1092-8472


  27 in total

1.  A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

Authors:  S R Targan; S B Hanauer; S J van Deventer; L Mayer; D H Present; T Braakman; K L DeWoody; T F Schaible; P J Rutgeerts
Journal:  N Engl J Med       Date:  1997-10-09       Impact factor: 91.245

2.  Double blind, placebo controlled trial of metronidazole in Crohn's disease.

Authors:  L Sutherland; J Singleton; J Sessions; S Hanauer; E Krawitt; G Rankin; R Summers; H Mekhjian; N Greenberger; M Kelly
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

3.  Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases.

Authors:  G Feutren; M J Mihatsch
Journal:  N Engl J Med       Date:  1992-06-18       Impact factor: 91.245

4.  Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study.

Authors:  R Löfberg; P Rutgeerts; H Malchow; C Lamers; A Danielsson; G Olaison; D Jewell; O Ostergaard Thomsen; H Lorenz-Meyer; H Goebell; H Hodgson; T Persson; C Seidegård
Journal:  Gut       Date:  1996-07       Impact factor: 23.059

5.  Second trial of mesalamine therapy in the treatment of active Crohn's disease.

Authors:  J Singleton
Journal:  Gastroenterology       Date:  1994-08       Impact factor: 22.682

6.  Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables.

Authors:  C Cammà; M Giunta; M Rosselli; M Cottone
Journal:  Gastroenterology       Date:  1997-11       Impact factor: 22.682

7.  Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease.

Authors:  R A Kozarek; D J Patterson; M D Gelfand; V A Botoman; T J Ball; K R Wilske
Journal:  Ann Intern Med       Date:  1989-03-01       Impact factor: 25.391

8.  An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin.

Authors:  C Prantera; F Zannoni; M L Scribano; E Berto; A Andreoli; A Kohn; C Luzi
Journal:  Am J Gastroenterol       Date:  1996-02       Impact factor: 10.864

9.  A comparison of budesonide with prednisolone for active Crohn's disease.

Authors:  P Rutgeerts; R Löfberg; H Malchow; C Lamers; G Olaison; D Jewell; A Danielsson; H Goebell; O O Thomsen; H Lorenz-Meyer
Journal:  N Engl J Med       Date:  1994-09-29       Impact factor: 91.245

10.  Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis.

Authors:  D C Pearson; G R May; G H Fick; L R Sutherland
Journal:  Ann Intern Med       Date:  1995-07-15       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.